Erythropoietin and organ protection: Lessons from negative clinical trials

Critical Care

Volumn 18, Issue 5, 2014, Pages

  Pearl, Ronald G ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROPOIETIN; ANTIANEMIC AGENT;

ACUTE KIDNEY FAILURE; ADULT RESPIRATORY DISTRESS SYNDROME; APOPTOSIS; ARTICLE; CEREBROVASCULAR ACCIDENT; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL (TOPIC); CORONARY ARTERY BLOOD FLOW; ERYTHROPOIESIS; HEART FAILURE; HEART VALVE SURGERY; HUMAN; INFLAMMATION; NONHUMAN; OUTCOME ASSESSMENT; OXIDATIVE STRESS; SEPSIS; ACUTE KIDNEY INJURY; FEMALE; HEART VALVE DISEASES; MALE; POSTOPERATIVE COMPLICATIONS;

ACUTE KIDNEY INJURY; ERYTHROPOIETIN; FEMALE; HEART VALVE DISEASES; HEMATINICS; HUMANS; MALE; POSTOPERATIVE COMPLICATIONS;

EID: 84910046131     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/s13054-014-0526-9     Document Type: Article

References (17)

1. Kim JH, Shim JK, Song JW, Song Y, Kim HB, Kwak YL. Effect of erythropoietin on the incidence of acute kidney injury following complex valvular heart surgery: a double blind, randomized clinical trial of efficacy and safety. Crit Care 2013, 17:R254. 10.1186/cc13081, 24156702.
2. Moore EM, Bellomo R, Nichol AD. Erythropoietin as a novel brain and kidney protective agent. Anaesth Intensive Care 2011, 39:356-372. 21675055.
3. Ehrenreich H, Weissenborn K, Prange H, Schneider D, Weimar C, Wartenberg K, Schellinger PD, Bohn M, Becker H, Wegrzyn M, Jähnig P, Herrmann M, Knauth M, Bähr M, Heide W, Wagner A, Schwab S, Reichmann H, Schwendemann G, Dengler R, Kastrup A, Bartels C. Recombinant human erythropoietin in the treatment of acute ischemic stroke. Stroke 2009, 40:e647-e656. 10.1161/STROKEAHA.109.564872, 19834012.
4. Najjar SS, Rao SV, Melloni C, Raman SV, Povsic TJ, Melton L, Barsness GW, Prather K, Heitner JF, Kilaru R, Gruberg L, Hasselblad V, Greenbaum AB, Patel M, Kim RJ, Talan M, Ferrucci L, Longo DL, Lakatta EG, Harrington RA. Intravenous erythropoietin in patients with ST-segment elevation myocardial infarction: REVEAL: a randomized controlled trial. JAMA 2011, 305:1863-1872. 10.1001/jama.2011.592, 21558517.
5. Prunier F, Bière L, Gilard M, Boschat J, Mouquet F, Bauchart JJ, Charbonnier B, Genée O, Guérin P, Warin-Fresse K, Durand E, Lafont A, Christiaens L, Abi-Khalil W, Delépine S, Benard T, Furber A. Single high-dose erythropoietin administration immediately after reperfusion in patients with ST-segment elevation myocardial infarction: results of the erythropoietin in myocardial infarction trial. Am Heart J 2012, 163:200-207. 10.1016/j.ahj.2011.11.005, 22305837.
6. Swedberg K, Young JB, Anand IS, Cheng S, Desai AS, Diaz R, Maggioni AP, McMurray JJ, O'Connor C, Pfeffer MA, Solomon SD, Sun Y, Tendera M, van Veldhuisen DJ. Treatment of anemia with darbepoetin alfa in systolic heart failure. N Engl J Med 2013, 368:1210-1219. 10.1056/NEJMoa1214865, 23473338.
7. Ghali JK, Anand IS, Abraham WT, Fonarow GC, Greenberg B, Krum H, Massie BM, Wasserman SM, Trotman ML, Sun Y, Knusel B, Armstrong P. Randomized double-blind trial of darbepoetin alfa in patients with symptomatic heart failure and anemia. Circulation 2008, 117:526-535. 10.1161/CIRCULATIONAHA.107.698514, 18195176.
8. Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, Reddan D. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006, 355:2085-2098. 10.1056/NEJMoa065485, 17108343.
9. Drüeke TB, Locatelli F, Clyne N, Eckardt KU, Macdougall IC, Tsakiris D, Burger HU, Scherhag A. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006, 355:2071-2084. 10.1056/NEJMoa062276, 17108342.
10. Tonia T, Mettler A, Robert N, Schwarzer G, Seidenfeld J, Weingart O, Hyde C, Engert A, Bohlius J. Erythropoietin or darbepoetin for patients with cancer. Cochrane Database Syst Rev 2012, 12. 23235597.
11. Sureshkumar KK, Hussain SM, Ko TY, Thai NL, Marcus RJ. Effect of high-dose erythropoietin on graft function after kidney transplantation: a randomized, double-blind clinical trial. Clin J Am Soc Nephrol 2012, 7:1498-1506. 10.2215/CJN.01360212, 22745272.
12. Oh SW, Chin HJ, Chae DW, Na KY. Erythropoietin improves long-term outcomes in patients with acute kidney injury after coronary artery bypass grafting. J Korean Med Sci 2012, 27:506-511. 10.3346/jkms.2012.27.5.506, 22563215.
13. de Seigneux S, Ponte B, Weiss L, Pugin J, Romand JA, Martin PY, Saudan P. Epoetin administrated after cardiac surgery: effects on renal function and inflammation in a randomized controlled study. BMC Nephrol 2012, 13:132. 10.1186/1471-2369-13-132, 23033926.
14. Endre ZH, Walker RJ, Pickering JW, Shaw GM, Frampton CM, Henderson SJ, Hutchison R, Mehrtens JE, Robinson JM, Schollum JB, Westhuyzen J, Celi LA, McGinley RJ, Campbell IJ, George PM. Early intervention with erythropoietin does not affect the outcome of acute kidney injury (the EARLYARF trial). Kidney Int 2010, 77:1020-1030. 10.1038/ki.2010.25, 20164823.
15. Wu WT, Hu TM, Lin NT, Subeq YM, Lee RP, Hsu BG. Low-dose erythropoietin aggravates endotoxin-induced organ damage in conscious rats. Cytokine 2010, 49:155-162. 10.1016/j.cyto.2009.11.002, 20004111.
16. Sølling C, Christensen AT, Nygaard U, Krag S, Frøkiaer J, Wogensen L, Krog J, Tønnesen EK. Erythropoietin does not attenuate renal dysfunction or inflammation in a porcine model of endotoxemia. Acta Anaesthesiol Scand 2011, 55:411-421. 10.1111/j.1399-6576.2011.02396.x, 21342148.
17. Freddolino PL, Tavazoie S. The dawn of virtual cell biology. Cell 2012, 150:248-250. 10.1016/j.cell.2012.07.001, 22817888.